uncertain growth lead downgrad
downgrad sell rate downgrad
tp previous tp base
forward price-to-earnings multipl adjust ep
provid upsid potenti
estim base follow factor declin
revenu core product enbrel growth newli
launch product declin net sell price
report strong growth revenu due
growth newli launch product total revenu increas
non-gaap ep grew
revenu earn
estim
mn except ep
howev report weak guidanc due
continu declin revenu enbrel due biosimilar
competit revenu guidanc
non-gaap ep guidanc per share
expect declin revenu due declin
sale top-sel drug enbrel due biosimilar
competit also declin net sell price
product sale also declin blockbust
product like neulasta aranesp epogen due biosimilar
compani name inc tickeramgnstock ratingselldowngradeindustri viewoverweightcautiouspric feb week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha inc februari
incom statement
non-
per share item
product perform develop
valuat consensu perform
six drug gener double-digit
growth cholesterol drug repatha led way sale
soar competit environ
could soon get tougher repatha well sanofi
regeneron recent announc major price cut
cholesterol drug praluent could take toll
biggest overal winner though osteoporosi
drug prolia increas sale
one new drug two new biosimilar launch
contribut solid revenu sale aimovig
total made
biosimilar key part growth strategi
european launch amjevita biosimilar world
best-sel drug humira go well
four biosimilar develop
howev success biosimilar
dampen bit failur win fda approv
kanjinti june biotech resubmit file
approv biosimilar cancer drug herceptin
cautiou regard growth due
uncertainti pipelin howev
blockbust product prolia aimovig
success wont enough off-set declin older
drug like enbrel neulasta
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date ex-dividend date feb last split factor new per last split date inform amgen inc februari
incom statement
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg oper oper profit interest interest incom incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli inc februari
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in capital- retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item amgen inc februari
flow oper activ increas compar due
improv work capit
provid invest activ compar cash use invest
activ increas due net cash inflow relat market secur
use financ activ compar due
repurchas common stock payment dividend repay debt
withhold tax aris share withheld share-bas payment
depreciation- defer incom oper increas decreas increas decreas current decreas increas decreas increas current liabilities- decreas increas work capital- non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant acquisitions- net invest financ activitiesissu debt- issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate changes- net chang begin end inc februari
report growth revenu continu solid oper
perform due double-digit growth new recent launch
increas
compar
total revenu increas compar
total product revenu increas
compar new recent launch
product includ repatha prolia kyproli xgeva show double-
digit growth total revenu decreas
compar
increas
compar
gaap sale increas compar
gaap sale product revenu
compar sale margin decreas
due lower royalti cost impact hurrican maria charg
off-set partial higher cost manufactur higher acquisition-rel
non-gaap sale compar
non-gaap cog product sale decreas
compar
sg expens increas compar
sg expens product revenu
increas compar increas
due invest product launch market product support
off-set partial favor comparison hurrican maria-rel charg
non-gaap sg expens increas compar
non-gaap sg expens product sale
increas compar
 expens increas compar
 expens total revenu
compar
non-gaap expens increas
compar non-gaap expens
product sale compar
oper expens decreas compar
oper expens increas
compar non-gaap oper expens
increas compar
oper incom increas compar
non-gaap oper incom declin
compar
oper margin decreas compar
non-gaap oper margin
compar
interest expens increas compar
interest incom net decreas
compar
increas
compar
decreas
compar
net loss
tax rate compar due
 corpor tax reform non-gaap tax rate decreas
compar
gaap net incom decreas compar net loss
non-gaap net incom increas
compar
gaap ep compar non-
gaap ep increas compar
total revenu increas compar
total product sale increas
compar total product sale increas
compar total revenu
increas compar
sale increas compar
sale product revenu declin
compar decreas due lower royalti
cost expens relat hurrican maria lower acquisition-
relat amort intang asset off-set partial higher
 expens increas compar
 expens product revenu
compar increas expens due
higher spend earli pipelin later-stag clinic program well
extern busi develop expens research earli pipelin off-set
partial lower market product support non-gaap decreas
compar
sg expens increas compar
non-gaap sg expens increas
compar sg product sale
compar increas sg expens
due invest product launch market product
total oper expens increas compar
oper incom increas
compar oper margin
compar
interest expens increas compar
due impact rise interest rate variable-r debt
compar
increas
compar
interest incom net decreas
compar decreas interest incom
net due higher invest loss lower interest incom result
liquid portion portfolio off-set partial gain
equiti invest net gain recogn connect
acquisit k-a
tax rate compar non-
tax rate decreas compar
net incom increas compar
non-gaap net incom increas compar
ep increas compar
non-gaap ep increas
compar
interest
incom net decreas
compar
increas
compar
market six therapeut area cardiovascular neurosci
oncology/hematolog inflamm nephrolog bone health
princip product neulasta enbrel sensipar/mimpara prolia
aranesp xgeva epogen also market number product
parsabiv imlyg corlanor aimovig kanjinti
total product sale increas compar
due higher unit demand total product sale increas
compar
total product sale increas
compar total product sale rest
world increas compar
total revenu prolia increas
compar total revenu increas
compar increas due
higher unit demand
total revenu increas
compar total revenu rest world
increas compar
total revenu xgeva increas
compar total revenu increas
compar increas due
higher unit demand
total revenu increas
compar total revenu rest world
increas compar
total revenu prolia
increas
compar
total revenu xgeva
increas
compar
total revenu kyproli increas
compar total revenu increas
compar
total revenu increas
compar total revenu rest world
increas compar
total revenu parsabiv compar
total revenu compar
total revenu total revenu
rest world
total revenu
kyproli increas
compar
total revenu
repatha increas
compar
total revenu repatha increas
compar total revenu increas
compar
total revenu increas
compar total revenu rest world
compar
total revenu sensipar increas
compar total revenu increas
compar increas due
increas net sell price unit state off-set partial
total revenu increas compar
total revenu rest world decreas
compar
total revenu nplate increas
compar total revenu increas
compar
total revenu increas
compar total revenu rest world
increas compar
total revenu blyncyto increas
compar total revenu increas
compar
total revenu increas
compar total revenu rest world
increas compar
total revenu vectibix increas
compar total revenu increas
compar
total revenu increas
compar total revenu rest world
increas compar
total revenu nplate
increas
compar
total revenu
blyncyto increas
compar
total revenu aranesp decreas
compar total revenu declin
compar declin due
impact competit unit demand
total revenu declin
compar total revenu rest world
compar
total revenu epogen decreas
compar total revenu declin
compar decreas epogen
sale due decreas net sell price due contractu term
negoti davita inc
total revenu
aranesp decreas
compar
total revenu enbrel
decreas
compar
total revenu enbrel decreas
compar total revenu declin
compar due lower unit demand
net sell price
total revenu declin
compar total revenu rest world
declin compar
total revenu aimovig
total revenu decreas
compar total revenu declin
compar
total revenu declin
compar total revenu rest world
decreas compar
total revenu neulasta increas
compar total revenu decreas
compar decreas due
favor chang account estim product return
off-set partial favor chang inventori neulasta sale
includ order govern
total revenu decreas
compar total revenu rest world
increas compar
total revenu
decreas
compar
total revenu
neulasta increas
compar
follow signific develop
data phase studi kyproli dexamethason kd
darzalexv kd relaps refractori multipl myeloma expect
approv europ treatment adult
b-precursor first second complet remiss minim
bcma bite bite
first-in-human data present annual meet
approv treatment pediatr patient immun
submit sbla treatment adult itp month less
insuffici respons corticosteroid immunoglobulin
indic china expand reduc risk myocardi infarct
stroke coronari revascular adult establish
repatha indic
china expand reduc
risk myocardi
infarct stroke
adult establish
approv japan treatment osteoporosi men
postmenopaus women high risk fractur
fda advisori committe vote favor approv treatment
postmenopaus women osteoporosi high risk fractur
regulatori submiss complet eu decemb
biolog licens applic resubmit fda decemb
even approv
japan treatment
osteoporosi men
high risk fractur
submiss complet
 eu decemb
januari
phase studi rheumatoid arthriti met primari secondari
phase data non-hodgkin lymphoma expect
phase studi paroxysm nocturn hemoglobinuria screen
basi ep
rang
tax rate
rang
growth revenu
due growth
total revenu expect rang
basi ep rang tax rate
rang
non-gaap basi ep rang tax rate
rang
capit expenditur
report strong growth revenu due growth newli
launch product total revenu increas non-
gaap ep grew
total product sale increas revenu
increas due larg y/i favor impact mileston
payment non-gaap oper expens increas y/i
due increas invest launch product exceed
benefit on-going transform initi
prolia deliv anoth strong quarter sale increas y/i driven
volum growth prolia grew expect prolia
remain strong growth driver
portfolio kyproli xgeva nplate vectibix blincyto imlyg
collect total quarter grow y/i may
period quarterli fluctuat due purchas pattern expect
portfolio continu growth engin provid foundat
innov biosimilar addit oncolog portfolio
xgeva grew y/i due volum growth share
 amgen share multipl myeloma patient continu grow steadili
label expans xgeva grew
kyproli grew y/i due growth market outsid
 sinc launch kyproli deliv suit clinic evid
demonstr abil meaning extend overal surviv patient
relaps refractori multipl myeloma
pipelin includ eight late-stag clinic program one
promis candid tezepelumab partner astrazeneca
evalu drug phase clinic studi treat asthma
phase studi treat atop dermat
gener free cash flow free cash
flow due improv work capit off-set partial
amgen dividend per share paid dec
repres increas versu amgen dividend
per share declar dec paid march
stockhold record feb repres increas
paid previou four quarter
repurchas share common stock total
cost repurchas share common stock
total cost remain
continu solid oper perform met
exceed long-term financi commit encourag
long-term growth prospect driven portfolio newer product pipelin
on-going success intern expans
kyproli grew y/i
due
growth market outsid
oper perform
met exceed
long-term financi
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
product perform develop
valuat consensu perform
revenu growth compar
ep growth compar
net margin increas compar
oper margin compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth inc februari
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale amgen inc februari
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset amgen inc februari
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item amgen inc februari
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc net chang capit free inc februari
price-to-earnings trail current price-to-earnings
averag price-to-earnings due declin stock price expect forward price-to-earnings
incom statement
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc capit research global fmr primecap manag america northern trust geod capit manag top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard vanguard/primecap invest compani capit world growth incom capit incom builder spdr etf amcap growth fund america vanguard institut fund-institut competit
develop receiv nmpa approv repatha evolocumab china reduc risk cardiovascular eventsjanuari thenat medic product administr nmpa approv new indic repatha evolocumab first inhibitor inchinafor adult establish atherosclerot cardiovascular diseas ascvd reduc risk myocardi infarct stroke coronari revascular european commiss approv blincyto blinatumomab patient philadelphia chromosom neg minim residu disease-posit b-cell precursor acut lymphoblast leukemiajanuari theeuropean commiss ec approv expand indic blincyto blinatumomab monotherapi includ adult patient withphiladelphiachromosom neg ph- posit b-cell precursor acut lymphoblast leukemia first second complet remiss minim residu diseas mrd greater equal percent approv base data phase blast studi frontlin relapsed/refractori largest prospect trial mrd-posit ever conduct blincyto bispecif cell engag bite first biteimmunotherapi receiv regulatori approv global even romosozumab receiv approv japan treatment osteoporosi patient high risk fracturejanuari ucb announc thejapanes ministri labor welfareha grant market author even romosozumab treatment osteoporosi patient high risk ucb co-develop even world-wide develop injapanb led astella biopharma joint ventur betweenandastella pharma inc headquart intokyo submit supplement biolog licens applic nplate romiplostim decemb submiss supplement biolog licens applic sbla theu food drug administr fda nplate romiplostim includ treatment adult patient immun thrombocytopenia itp itp month less insuffici respons corticosteroid immunoglobulin splenectomi inc februari
incom statement
non-
per share item
product perform develop
valuat consensu perform
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit inc februari
consensu view analyst trend stock
forecast
compar
forward price-to-earnings
compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonamgnindustri avg avgprice/earn yield inc februari
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr inc februari
incom statement
non-
per share item
product perform develop
valuat consensu perform
stock price movement volatil quarter dip decemb
stock gave return period averag daili volum share trade
quarter
stock price show huge fluctuat year surg novemb
stock price declin result due weak guidanc
stock given return past one year rang stock
stock price volatil till later show upward trend surg
stock given return past due growth busi
revenu grew due double-digit growth new recent launch
product includ repatha prolia aimovig recommend sell rate tp
base forward price-to-earnings multipl adjust ep base uncertainti
growth compani
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
